Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 123473

1.

Development of a booklet on insulin therapy for children with diabetes mellitus type 1.

Moura DJ, Moura ND, Menezes LC, Barros AA, Guedes MV.

Rev Bras Enferm. 2017 Jan-Feb;70(1):7-14. doi: 10.1590/0034-7167-2016-0183. Portuguese, English.

2.

Predictors of subclinical atherosclerosis evaluated by carotid intima-media thickness in asymptomatic young women with type 1 diabetes mellitus.

Kupfer R, LarrĂºbia MR, Bussade I, Pereira JR, Lima GA, Epifanio MA, Schettino CD, Momesso DP.

Arch Endocrinol Metab. 2017 Feb 16:0. doi: 10.1590/2359-3997000000255. [Epub ahead of print]

3.

Decreased levels of Fibroblast Growth Factor 21 are correlated with improved hypoglycemia in patients with insulinoma.

Li X, Yu H, Yin J, Li L, Zhou J, Li M, Li Q, Chen H, Liu F, Bao Y, Han J, Jia W.

Sci Rep. 2017 Feb 22;7:43123. doi: 10.1038/srep43123.

4.

Effect of Helicobacter pylori on metabolic syndrome parameters in diabetic patients.

Vafaeimanesh J, Bagherzadeh M, Mirzaei A, Parham M, Norouzinia M, Vafaee R.

Gastroenterol Hepatol Bed Bench. 2016 Dec;9(Suppl1):S36-S41.

PMID:
28224026
5.

Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus - current status.

Ganesan P, Arulselvan P, Choi DK.

Int J Nanomedicine. 2017 Feb 9;12:1097-1111. doi: 10.2147/IJN.S124601. Review.

6.

Efficacy and Safety of Metreleptin Therapy in Patients With Type 1 Diabetes: A Pilot Study.

Vasandani C, Clark GO, Adams-Huet B, Quittner C, Garg A.

Diabetes Care. 2017 Feb 21. pii: dc161553. doi: 10.2337/dc16-1553. [Epub ahead of print]

PMID:
28223297
7.

A MODEL OF CHRONIC DIABETIC POLYNEUROPATHY: BENEFITS FROM INTRANASAL INSULIN ARE MODIFIED BY SEX AND RAGE DELETION.

de la Hoz CL, Cheng C, Fernyhough P, Zochodne DW.

Am J Physiol Endocrinol Metab. 2017 Feb 21:ajpendo.00444.2016. doi: 10.1152/ajpendo.00444.2016. [Epub ahead of print]

PMID:
28223295
8.

Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.

Jeanes YM, Reeves S.

Nutr Res Rev. 2017 Feb 22:1-9. doi: 10.1017/S0954422416000287. [Epub ahead of print]

PMID:
28222828
9.

Serum betatrophin levels are increased and associated with insulin resistance in patients with polycystic ovary syndrome.

Qu Q, Zhao D, Zhang F, Bao H, Yang Q.

J Int Med Res. 2017 Feb;45(1):193-202. doi: 10.1177/0300060516680441.

PMID:
28222635
10.

Type 1 Diabetes Mellitus and Cognitive Impairments: A Systematic Review.

Li W, Huang E, Gao S.

J Alzheimers Dis. 2017 Feb 10. doi: 10.3233/JAD-161250. [Epub ahead of print]

PMID:
28222533
11.

Factors associated with increased irisin levels in the type 1 diabetes mellitus.

Ates I, Arikan MF, Erdogan K, Kaplan M, Yuksel M, Topcuoglu C, Yilmaz N, Guler S.

Endocr Regul. 2017 Jan 1;51(1):1-7. doi: 10.1515/enr-2017-0001.

PMID:
28222023
12.

Identification of candidate biomarkers for the prediction of gestational diabetes mellitus in the early stages of pregnancy using iTRAQ quantitative proteomics.

Zhao D, Shen L, Wei Y, Xie J, Chen S, Liang Y, Chen Y, Wu H.

Proteomics Clin Appl. 2017 Feb 21. doi: 10.1002/prca.201600152. [Epub ahead of print]

PMID:
28220636
13.

Cardio-protective effects of pectin-insulin patch in streptozotocin-induced diabetic rats Beneficial effects of insulin patch.

Sibiya N, Ngubane P, Mabandla M.

J Diabetes. 2017 Feb 20. doi: 10.1111/1753-0407.12538. [Epub ahead of print]

PMID:
28220624
14.

Supporting patients with type 1 diabetes using continuous subcutaneous insulin infusion therapy: Difficulties, disconnections, and disarray.

Perry L, James S, Gallagher R, Dunbabin J, Steinbeck K, Lowe J.

J Eval Clin Pract. 2017 Feb 21. doi: 10.1111/jep.12703. [Epub ahead of print]

PMID:
28220558
15.

Suppression of islet homeostasis protein thwarts diabetes mellitus progression.

Oh SH, Jorgensen ML, Wasserfall CH, Gjymishka A, Petersen BE.

Lab Invest. 2017 Feb 20. doi: 10.1038/labinvest.2017.15. [Epub ahead of print]

PMID:
28218739
16.

Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease.

Targher G, Byrne CD.

Nat Rev Nephrol. 2017 Feb 20. doi: 10.1038/nrneph.2017.16. [Epub ahead of print] Review.

PMID:
28218263
17.

How many oral antidiabetic drugs before insulin?

Kelwade J, Parekh H, Dukle V, Sethi BK.

Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):249-250. doi: 10.4103/2230-8210.195994.

18.

Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.

Kalra S, Ghosh S, Aamir AH, Ahmed MT, Amin MF, Bajaj S, Baruah MP, Bulugahapitiya U, Das AK, Giri M, Gunatilake S, Mahar SA, Pathan MF, Qureshi NK, Raza SA, Sahay R, Shakya S, Shreshta D, Somasundaram N, Sumanatilleke M, Unnikrishnan AG, Wijesinghe AM.

Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):210-230. doi: 10.4103/2230-8210.196029. Review.

19.

A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.

Prasanna Kumar KM, Ghosh S, Canovatchel W, Garodia N, Rajashekar S.

Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):196-209. doi: 10.4103/2230-8210.196016. Review.

20.

Reported hypoglycemia in Type 2 diabetes mellitus patients: Prevalence and practices-a hospital-based study.

Shriraam V, Mahadevan S, Anitharani M, Jagadeesh NS, Kurup SB, Vidya TA, Seshadri KG.

Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):148-153. doi: 10.4103/2230-8210.196002.

Items per page

Supplemental Content

Loading ...
Support Center